EKF Diagnostics, a global in vitro diagnostics company based in Cardiff, UK, is presenting its STAT-Site WB dual analyze measurement handheld β-ketone and glucose analyzer at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo this week in Atlanta.
The handheld analyzer is designed to provide reliable and efficient β-ketone and glucose measurement from whole blood in seconds. The CLIA-waived and CE-marked device can be used in professional settings to monitor the effectiveness of diabetes control programs.
EKF will also introduce its Hemo Control hemoglobin analyzer to the U.S. market, which provides near patient hemoglobin and hematocrit results in one test in as quickly as 25 seconds.
EKF’s team of point-of-care and central laboratory diagnostics experts at the Georgia World Congress Center in Atlanta this week will also highlight the Lucica Glycated Albumin-L. Manufactured by Asahi Kasei Pharma, this specific test for glycated albumin is FDA cleared for sale in the United States, where it is sold exclusively by EKF Diagnostics. This established test enables intermediate term glycemic monitoring of diabetics over the preceding two to three weeks.
The Lucica Glycated Albumin-L is a quantitative, enzymatic test for use on compatible clinical chemistry analyzers as a user-defined method. The Lucica method has appeared in numerous published studies.
According to the company, glycated albumin levels are not affected by the life span of red blood cells, and therefore are a useful substitute when the HbA1c interpretation is problematic, such as in the presence of hemoglobinopathies, iron deficiency, and anemias. Another key feature of glycated albumin is that it changes more rapidly and markedly than HbA1c. Therefore, glycated albumin is a good marker to monitor the effects of changes in therapy in patients with diabetes when more rapid treatment responses are needed.
The STAT-Site WB and Lucica Glycated Albumin-L test are part of a suite of other diabetes care products that EKF will be showcasing at 2021 AACC. These include the Beta-Hydroxybutyrate LiquiColor Assay (B-HB) and Nitro-Tab Ketone Tablets, both of which provide quick and simple tests for ketosis.
Other product highlights for point-of-care and central laboratory testing include the hand-held hemoglobin analyzer DiaSpect as well as the HemoPoint H2, which offers both hemoglobin and hematocrit results in one test within 30 to 60 seconds. The Biosen RUO glucose and lactate analyzer will also be featured.
EKF will also discuss its growing EKF Life Sciences business, which provides contract manufacturing services, as well as manufacturing diagnostic enzymes for use in medical diagnostics, pharmaceuticals, and industry. This follows recent significant investment in the company’s longstanding fermentation facility in Elkhart, Ind, where it has been manufacturing enzymes and related biomolecules from bacterial fermentation since 1983.
For more information, visit EKF.
Featured Image: The STAT-Site WB analyzer is designed to deliver reliable and efficient β-ketone and glucose measurement from whole blood in seconds. Photo: EKF